A track record of success. Running faster than the pack.
“Our team has a proven record developing and commercializing therapies that improve patient care and outcomes”.
[image placeholder – do not delete]
The foremost purpose of each of our leadership teams is to provide support, guidance and expertise to ensure the success of each development program within our portfolio of companies. Cognizant of our role as a critical growth engine for Sumitomo Dainippon Pharma, we continually seek new assets to enhance our robust and diverse pipeline and are transforming the drug development process to deliver new medicines to market faster.
We bring new medicines to patients more rapidly.Dan Rothman, Chief Information Officer
Q&A with Dan Rothman, Chief Information Officer at Sumitovant
Sumitovant’s Chief Information Officer, Dan Rothman, elaborates on our key technology platforms and how they may potentially help us bring new medicines more quickly to those who need them most.
Yuichiro Haruyama serves as Executive Vice President, Finance & Corporate Strategy and a member of the board of Sumitovant Biopharma. Mr. Haruyama was instrumental in creating the broad strategic partnership between Sumitomo Dainippon Pharma and Roivant Sciences in 2019, including forming Sumitovant Biopharma. He started his career at Sumitomo Chemical, a leading Japanese chemical company, in 1993 and, since then, he has played a leading role in global pharmaceutical/chemical operations, corporate strategy, business development and finance. At Sumitomo Chemical, he was responsible for designing and implementing strategy for OLED (organic light-emitting diode) business, including a number of partnerships with global electronics companies, as well as oversaw its global operations. As Sumitomo Dainippon Pharma, he served as a key member in developing the corporate mid-term business plan in 2019, setting up and managing global business operations, such as the U.S., UK and Chinese affiliate companies, and leading a number of M&A efforts. Mr. Haruyama earned a Bachelor of Science degree in Business and Commerce at Keio University in Tokyo and an MBA in finance from Indiana University in Bloomington, Indiana.